Trial reportActas espanolas de psiquiatria2025
Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia.
Trial report in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05345977 (eMotiph), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
eMotiph: Smart and Innovative E-mental Health Solution to Manage Patients With Schizophrenia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a heterogeneous mental health disorder associated with severe disability. Approximately 30% of patients do not respond to pharmacological treatment, a condition known as treatment-resistant schizophrenia (TRS). Emerging digital solutions could help to improve the treatment of this population. Although the importance of characterising the patient journey (PJ) is widely recognised, and previously published in schizophrenia, this has never been done in patients with TRS to identify their specific needs and select digital approaches to fill the healthcare gaps. Therefore, this study aimed to (1) characterise the PJ in patients with TRS, (2) determine the key needs of these patients, and (3) identify digital solutions that could help to address those needs.
methodsThree focus groups were constituted: (1) patients with TRS (n = 6); (2) informal caregivers (n = 4); and (3) social/healthcare professionals (n = 16). An advisory board (n = 11) was also created. We used the PJ and patient experience (PEx) methodologies, which place the user experience at the centre of the process. A five-step process was used to define the PJ, to identify patient and caregiver archetypes, to determine the needs and preferences of patients and caregivers, and to identify solutions (technological and others) to address those needs.
resultsWe identified the archetypes of patients with TRS and informal caregivers. Nine stages of the PJ were identified: previous symptomatology; emergency care; hospitalization; therapeutic guidelines; outpatient care; diagnosis; disorder control; exacerbations; and risk behaviours. Six key needs were identified: better care during emergencies; improved understanding of the disorder and adverse events; better communication during diagnosis; better control and monitoring of the disorder; better identification of early warning signs; and immediate professional attention. Twenty-six specific initiatives aimed at improving the PEx and care processes were defined.
conclusionsThis study characterised the PJ in patients with TRS. The findings of this study reveal the key areas of the recovery process that need improvement. Importantly, we developed a set of twenty-six specific initiatives to improve clinical outcomes. The main need identified by participants was for non-pharmacological interventions.
trial registrationClinicalTrials.gov NCT05345977.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.